Charles Schwab Investment Management Inc Atara Biotherapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Atara Biotherapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 761,360 shares of ATRA stock, worth $6.47 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
761,360
Previous 745,145
2.18%
Holding current value
$6.47 Million
Previous $380,000
38.16%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding ATRA
# of Institutions
87Shares Held
85MCall Options Held
18.4KPut Options Held
51.3K-
Eco R1 Capital, LLC San Francisco, CA10.2MShares$86.4 Million0.2% of portfolio
-
Redmile Group, LLC San Francisco, CA9.26MShares$78.7 Million0.25% of portfolio
-
Black Rock Inc. New York, NY6.83MShares$58.1 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC6.58MShares$55.9 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il6.51MShares$55.4 Million0.0% of portfolio
About Atara Biotherapeutics, Inc.
- Ticker ATRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,362,304
- Market Cap $802M
- Description
- Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...